Abstract
Abstract
Background
Exercise intolerance is among the most common symptoms experienced by patients with chronic obstructive pulmonary disease (COPD), which is associated with lung dynamic hyperinflation (DH). There was evidence that positive expiratory pressure (PEP), which could be offered by less costly devices, could reduce DH. The purpose of this study was to evaluate the efficacy and safety of long-term domiciliary use of PEP device in subjects with COPD.
Methods
A randomized controlled trial was conducted and 25 Pre-COPD or mild-to-very severe subjects with COPD were randomized to intervention group (PEP device, PEP = 5 cmH2O, n = 13) and control group (Sham-PEP device, PEP = 0 cmH2O, n = 12). PEP device was a spring-loaded resistor face mask. Subjects were treated 4 h per day for a total of 2 months. Six-minute walk test (6MWT), pulmonary function, the Modified British Medical Research Council score, and partial pressure of end-tidal carbon dioxide were evaluated at baseline and after two months.
Results
The 6MWD (− 71.67 ± 8.70 m, P < 0.001), end-dyspnea (P = 0.002), and end-fatigue (P = 0.022) improved significantly in the intervention group when compared with the control group. All subjects in the intervention group reported that 4 h of daily use of the PEP device was well tolerated and accepted and there were no adverse events.
Conclusion
Regular daily use of PEP device is safe and may improve exercise capacity in subjects with COPD or pre-COPD. PEP device could be used as an add-on to pulmonary rehabilitation programs due to its efficacy, safety, and low cost.
Trial registration: The study was prospectively registered on ClinicalTrials.gov (NCT04742114).
Funder
Qilu Hospital of Shandong University
Publisher
Springer Science and Business Media LLC
Subject
Pulmonary and Respiratory Medicine
Reference31 articles.
1. Maltais F, Decramer M, Casaburi R, Barreiro E, Burelle Y, Debigare R, Dekhuijzen PNR, Franssen F, Gayan-Ramirez G, Gea J, et al. An Official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease executive summary. Am J Respir Crit Care Med. 2014;189(9):1121–37.
2. Global Strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease. GOLD 2021.
3. Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–17.
4. Organisation WH. The top 10 causes of death. Available at: https://www.whoint/news-room/fact-sheets/detail/the-top-10-causes-of-death (2020).
5. Rossi A, Aisanov Z, Avdeev S, Di Maria G, Donner CF, Luis Izquierdo J, Roche N, Similowski T, Watz H, Worth H, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med. 2015;109(7):785–802.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献